Close Menu

NEW YORK – Investment bank Evercore ISI on Tuesday downgraded Qiagen's stock to an In Line rating from a previous Outperform rating and assigned a per-share price target of $42.

In a note to investors, Evercore ISI analyst Ross Muken and others said that although Qiagen appears that it will hit most of its long-term 2020 financial targets issued in 2016, recently issued long-term guidance of constant exchange rate growth of 8 percent to 9 percent by 2023 appears to be less of a sure thing.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Economist reports that it is increasingly easier to analyze the metabolites people give off, potentially revealing personal information about them.

A controversial paper on the gender gap in science has been corrected, according to BuzzFeed News.

The Los Angeles Times reports that only a third of California students meet the state's new science standards.

In Science this week: evidence of interbreeding between the ancestors of West Africans and an unknown archaic human, and more.